CN108949973A - The biomarker of trophocyte invasiveness exception and its application - Google Patents
The biomarker of trophocyte invasiveness exception and its application Download PDFInfo
- Publication number
- CN108949973A CN108949973A CN201810643550.3A CN201810643550A CN108949973A CN 108949973 A CN108949973 A CN 108949973A CN 201810643550 A CN201810643550 A CN 201810643550A CN 108949973 A CN108949973 A CN 108949973A
- Authority
- CN
- China
- Prior art keywords
- trophocyte
- mir
- invasiveness
- expression
- s1pr1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000090 biomarker Substances 0.000 title abstract description 7
- 108091043222 miR-181b stem-loop Proteins 0.000 claims abstract description 67
- 230000014509 gene expression Effects 0.000 claims abstract description 47
- 101000693265 Homo sapiens Sphingosine 1-phosphate receptor 1 Proteins 0.000 claims abstract description 30
- 102100025750 Sphingosine 1-phosphate receptor 1 Human genes 0.000 claims abstract description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 38
- 201000010099 disease Diseases 0.000 claims description 30
- 201000011461 pre-eclampsia Diseases 0.000 claims description 18
- 239000002679 microRNA Substances 0.000 claims description 17
- 206010028980 Neoplasm Diseases 0.000 claims description 16
- 201000011510 cancer Diseases 0.000 claims description 16
- 108091070501 miRNA Proteins 0.000 claims description 16
- 239000003153 chemical reaction reagent Substances 0.000 claims description 15
- 206010000234 Abortion spontaneous Diseases 0.000 claims description 13
- 208000000995 spontaneous abortion Diseases 0.000 claims description 13
- 230000008859 change Effects 0.000 claims description 5
- 238000001514 detection method Methods 0.000 claims description 5
- 239000003550 marker Substances 0.000 claims description 5
- 230000007423 decrease Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000009007 Diagnostic Kit Methods 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000035935 pregnancy Effects 0.000 abstract description 20
- 108090000623 proteins and genes Proteins 0.000 abstract description 12
- 230000009545 invasion Effects 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 9
- 230000002265 prevention Effects 0.000 abstract description 3
- 230000009456 molecular mechanism Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 18
- 210000002826 placenta Anatomy 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 9
- 238000003745 diagnosis Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 102100036189 C-X-C motif chemokine 3 Human genes 0.000 description 5
- 208000001362 Fetal Growth Retardation Diseases 0.000 description 5
- 206010070531 Foetal growth restriction Diseases 0.000 description 5
- 101000947193 Homo sapiens C-X-C motif chemokine 3 Proteins 0.000 description 5
- 230000004709 cell invasion Effects 0.000 description 5
- 208000030941 fetal growth restriction Diseases 0.000 description 5
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- 230000030279 gene silencing Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 3
- 102100036431 Calcineurin subunit B type 1 Human genes 0.000 description 3
- 101000714321 Homo sapiens Calcineurin subunit B type 1 Proteins 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 108091031103 miR-181a stem-loop Proteins 0.000 description 3
- 108091046591 miR-181a-4 stem-loop Proteins 0.000 description 3
- 108091049627 miR-181a-5 stem-loop Proteins 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 210000005059 placental tissue Anatomy 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 2
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 2
- 108700011259 MicroRNAs Proteins 0.000 description 2
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 2
- 206010036600 Premature labour Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 210000004252 chorionic villi Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108091055042 miR-181 stem-loop Proteins 0.000 description 2
- 108091073628 miR-181d stem-loop Proteins 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 208000026440 premature labor Diseases 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 206010067477 Cytogenetic abnormality Diseases 0.000 description 1
- 241000252212 Danio rerio Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 102100021090 Homeobox protein Hox-A9 Human genes 0.000 description 1
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 description 1
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 description 1
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 description 1
- 102100025304 Integrin beta-1 Human genes 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 101150080147 Ppp3r1 gene Proteins 0.000 description 1
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 description 1
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000007622 bioinformatic analysis Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 208000002296 eclampsia Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 108010027263 homeobox protein HOXA9 Proteins 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 108091048308 miR-210 stem-loop Proteins 0.000 description 1
- 108091048549 miR-29b stem-loop Proteins 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000028742 placenta development Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 101150024819 s1pr1 gene Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 208000029387 trophoblastic neoplasm Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention relates to the biomarker of trophocyte invasiveness exception and its applications, confirm the universal differential expression of miR-181b in the pregnancy related disorder tissue of trophocyte invasiveness exception, S1PR1 is the direct effect target gene of miR-181b, the discovery of the molecular mechanism of trophocyte invasive ability is influenced by miR-181b-S1PR1 access, the prevention and treatment of the pregnancy related disorder to be caused extremely by trophocyte invasion provides new thread and potential intervention target.
Description
Technical field
The present invention relates to the biomarker of trophocyte invasiveness exception and its mechanism study more particularly to miR-181b
And its downstream target gene S1PR1 is in the application as trophocyte invasiveness abnormality mark object.
Background technique
The invasion of trophocyte are embryo nidation and the essential process of placentation, this invasion and tumour cell
Invasion are shifted surprising similar, but are different from tumour cell, the invasion of trophocyte are had stringent by fine regulation
Space-time limitation.The invasiveness of trophocyte is moderate, is that the success or failure that physiology gestation is established, maintains and terminated in due course are crucial, and invade
It is unbalance to attack power, can cause a variety of pregnancy related disorders, and is related to each stage in pregnancy period: invasiveness crosses weak derivable and causes infertile, stream
The pathological pregnancies such as production, premature labor, fetal growth restriction, preeclampsia;It is too strong and Placenta acrreta and trophoblastic tumor can occur
(such as: suede cancer), these diseases are to threaten one of the arch-criminal of female youngster's life safety.According to statistics, pregnant Early-stage cervical cancer
Incidence be up to 2-4%;To middle pregnant stage in evening, premature labor 9.6%, fetal growth restriction 5%-10%, preeclampsia 3%-5%
Deng incidence all present and rise year by year situation.Therefore, angle is invaded from trophocyte, finds pregnancy related disorder and effectively prevents
It is very urgent to control measure.
It has been found that trophocyte invasiveness is not only related to the factors such as oxidative stress, hypoxemia, hormone, and by S1PR1,
The regulating and controlling effect of the signal paths such as the genes such as CsA, CXCL3 and MEK, ERK, Wnt.With to regulation information research go deep into, one
Class length only 22 bases, post-transcriptional level negative regulation gene expression tiny RNA (microRNA is also known as miRNA) enter grind
The visual field for the person of studying carefully.With the increase that miRNA function recognizes, the effect in pregnancy related disorder is also gradually taken off with mechanism
Show.Research is found: miR-210 is by regulating and controlling the migration of Ephrin-A3a, Homeobox-A9 expression inhibiting trophocyte and invading
It attacks;MiR-29b lowers MCL1, MMP2, VEGFA, ITGB1 expression, influences invasion, apoptosis and the angiogenesis of trophocyte;
MiR-195 low expression can influence ActRIIA expression reduction trophocyte invasiveness in placenta from patients with pre-eclampsia.
However existing research is made a general survey of, it is that (such as: preeclampsia, fetal growth restriction) are assessed from single disease
The correlation of miRNA and trophocyte invasiveness lack comprehensive analysis to such pregnancy related disorder.If can gather a variety of
The disease of trophocyte invasiveness exception, screens relative miRNA comprehensively, can not only increase to embryo nidation, placenta
The understanding of formation can also provide new target for the prevention and treatment of the diseases such as spontaneous abortion, preeclampsia, fetal growth restriction and suede cancer
Mark, therefore become the direction that we study.
Summary of the invention
The present invention provides a kind of miRNA markers in the diagnostic reagent for preparing trophocyte invasiveness exception related disease
In application, it is characterised in that the marker be miR-181b.
The present invention also provides the reagent of the expression for measuring miR-181a in manufacture for predicting object
Application in the kit of a possibility that trophocyte invasiveness exception related disease, wherein if the expression of miR-181a
It significantly increases or reduces relative to normal control, it is considered that trophocyte invasiveness exception related disease occurs for the object
A possibility that increase.
Further, the present invention provides a kind of diagnostic kit of trophocyte invasiveness exception related disease, and feature exists
Contain the reagent of detection miR-181b in the kit.
Preferably, the disease is selected from spontaneous abortion, preeclampsia, suede cancer.
In addition, present invention discover that miR-181b is preparing the application in the reagent for adjusting S1PR1 expression, wherein making
The reagent that miR-181b is overexpressed causes the expression of S1PR1 to decline, and the reagent of miR-181b low expression is made to lead to S1PR1's
Expression rises.
Further, the reagent be used to change trophocyte invasiveness.
Further, the reagent be used to treat trophocyte invasiveness exception related disease.
Preferably, the disease is selected from spontaneous abortion, preeclampsia, fetal growth restriction and suede cancer.
The present invention has the positive effect that:
1.miRNA is a kind of new biomarkers, not only stable, minimally invasive, be easy to detect, and quantitative accurate, will significantly
The abnormality diagnostic sensibility and specificity of trophocyte's invasiveness is improved, the success of such microRNA biomarker is opened
Hair is overturning to the traditional biological marker based on albumen, will start completely new situation for the prevention and treatment of pregnancy related disorder.
2. it is extremely related that miRNA marker miR-181b provided by the invention can be used as Accurate Diagnosis trophocyte invasiveness
The diagnosis marker of disease can avoid invasive diagnosis, and can carry out auxiliary diagnosis in early stage, thus further for clinician
Testing in depth testing provides foundation, quick and precisely to grasp the morbid state of patient and coincident with severity degree of condition, in time taking more individual character
The control prece of change provides support, delays and prevent progression of disease.
3. outer in addition to diagnosing, present invention demonstrates for miR-181b overexpression or the changeable trophocyte of silencing invade
Power is attacked, provides new therapeutic strategy for the treatment of pregnancy related disorder.
4. the present invention further demonstrates miR-181b for the mediating effect+6 of S1PR1, nourished for further further investigation
The relevant molecule mechanism and signal path of cell invasion power provide thinking.
Detailed description of the invention
Fig. 1 is the expression changing rule that miR-181b changes with trophocyte invasiveness.Wherein a:miR-181b and miR-
The expression of 181a, miR-181d in suede cancerous tissue, (* P<0.05vs NP, * * P>0.05vs NP, * * * P>0.05vs NP);
Expression of the b:miR-181b in the different trophocyte strain of invasiveness, (#P < 0.05vs JAR).
Fig. 2 is miR-181b expression in up-regulation JEG-3 and HTR-8/Svneo cell, and the invasiveness of cell changes situation.a:
Transwell test prompt cell invasion ability changes;B: invasion index, (* P < 0.05vs Scramble);C: gelatin zymogram
Invasive associated protein MMP-2/MMP-9 activity change is shown in experiment.
Fig. 3 is miR-181b target gene Bioinformatics Prediction.A: software prediction miR-181b possible target gene;b:
The bioinformatics feature of S1PR1 gene.
Fig. 4 is 3 prediction targets such as S1PR1 in the expression being overexpressed on miR-181b trophocyte.A:S1PR1 exists
The expression being overexpressed on JEG-3, HTR-8/Svneo cell strain of miR-181b, (* P < 0.05vs Scramble);b:CXCL3
Expression on JEG-3, HTR-8/Svneo cell strain for being overexpressed miR-181b;C:PPP3R1 is being overexpressed miR-181b's
Expression on JEG-3, HTR-8/Svneo cell strain.
Fig. 5 is the expression changing rule that S1PR1 changes with trophocyte invasiveness.(*P<0.05vs NP;**P<0.05vs
NV)。
Specific embodiment
Present invention will be described in further detail below with reference to the accompanying drawings, to enable those skilled in the art referring to specification text
Word can be implemented accordingly.
Embodiment 1: the screening of the miRNA of trophocyte invasiveness exception is participated in
The related disease tissue for having selected two kinds of typical trophocyte invasivenesses to weaken: Early-stage cervical cancer villus (takes it
Parent progesterone and Immune Indexes are normal, and exclude chromosome by chromosome karyotype analysis method through our hospital's pre-natal diagnosis center
Abnormal person) and placenta of preeclampsia, it is micro- using μ Paraflo using regions in first-trimester villi and normal placenta tissue as respective control
Fluid chip technology screens the consistent miRNAs of difference between two groups of diseases.
As the result is shown: compared with the control group, the miRNAs in spontaneous abortion villus and human placenta of preeclampsia expresses water
Averagely there is larger difference;But miRNAs expression difference is consistent and in only 25 of 5 times or more between two groups of diseases, wherein
16 expressions increase, 9 expressions decline.Chip results prompt, some miRNA may invade abnormal in trophocyte
Similar effect is played in relevant disease.Further we combine group difference, filter out 10 significant differences (> 5 times)
MiRNAs carry out quantitative PCR verifying.10 miRNAs quantitative results show, difference trend and chip data trend basic one
It causes.In this 10 miRNAs, miR-181b has attracted our attention.MiR-181b group difference is up to 9.4 (tires respectively
Disk) and 8.7 (villus) times.Further with the verifying of Real time round pcr, as a result it is consistent with chip.In figure: NP is normal tire
Disk, PE are placenta of preeclampsia, and NV is regions in first-trimester villi, and SA is spontaneous abortion villus.It is well known that miR-181 family is one
Star molecule extremely conservative in evolution, in a variety of diseases especially in terms of the generation of malignant tumour, development and its clinic diagnosis
Play important role;Existing numerous studies confirm that the migration invasion of miR-181 family and tumour cell are closely related.miR-
Specificity overexpression of the 181b in trophocyte invasiveness deficiency diseased tissue, prompts it may to trophocyte invasiveness
Have the function of similar.
Embodiment 2:miR-181b invades the expression in abnormal related disease in different trophocytes
The correlation of this three and trophocyte invasiveness for further evaluation, we invade too strong in trophocyte
It is verified on suede cancer sample.
50 chorionic villi of spontaneous abortion (trophocyte invasiveness is insufficient) is collected, with Normal villus tissue (trophocyte
Invasiveness is normal) as control;It is collected simultaneously 50 Cases with Preeclampsia placenta tissues (trophocyte invasiveness is insufficient), 50 suede cancers
Tissue specimen (trophocyte invasiveness is excessive), using normal placenta tissue (trophocyte invasiveness is normal) as control.Using
The expression of miR-181b, is commented in Real time PCR or Western Blot technology detection placenta, villus and suede cancerous tissue sample
Relationship between valence and trophocyte invasiveness.
Wherein, the standard in " gynecotokology " (the 7th edition) that 1. the diagnosis reference Le Jie of preeclampsia is edited: gestation 20 weeks
After, blood pressure >=140/90mmHg is spaced 6 hours, and has Urine proteins, Urine proteins >=300mg/24 hour or arbitrarily urinate >=
30mg/dL, interval are surveyed primary for 4 hours again.Preeclampsia group and normal pregnancy group in this research are single tire primipara, are selected a time
Cesarean section delivery, no smoking and pregnancy period high amount of drug take history, no infection history duration of pregnancy and internal disease.
2. suede cancer makes a definite diagnosis the histodiagnosis in main " gynecotokology " (the 7th edition) according to referring to Le Jie chief editor: in son
Transfer stove is shown in that trophocyte in blocks invades profit and necrotic hemorrhage outside palace muscle layer or uterus.Suede carninomatosis involved in this research does not connect per capita
It is transfused blood, immunization therapy.
3. spontaneous abortion refers to unused manual method, what is be discharged due to certain reason embryo or fetus automatically disengage shows
As.Chorionic villi collected is all from the patient that pregnant early stage (gestation is before 12 weeks) miscarries for the first time in this research, and the pregnancy period is without suction
Cigarette and high amount of drug take history, no infection history duration of pregnancy and internal disease, and progesterone and Immune Indexes are normal, and through chromosome core
Type analysis method excludes chromosome abnormality (routinely carrying out this work in our hospital's pre-natal diagnosis center).
As a result, it has been found that invaded in trophocyte on too strong suede cancer sample, miR-181a, miR-181d without significant difference, and
Specific low expression is presented in miR-181b (see Fig. 1 a).On this basis, we have detected miR-181b again and nourish in JAR suede cancer
Cell strain (low invasiveness), JEG-3 suede cancer trophocyte strain (high invasiveness) and HTR-8/Svneo villi trophocyte strain
Expression in (high invasiveness).The results show that miR-181b high is expressed in the jar cell of low invasion, and low expression is in increased resistance invasion
JEG-3 the and HTR-8/Svneo cell of attacking property (see Fig. 1 b).Result above and analysis prompt, miR-181b are not only expressed in taste
It supports in cell, but also extremely related with the trophocyte invasiveness of a variety of pregnancy related disorders.In figure: NP is normal placenta,
CH is suede cancerous tissue, and JEG-3, JAR are the trophocyte strain of suede cancer, and HTR is the trophocyte strain of HTR-8/Svneo villi.
Influence of the embodiment 3:miR-181b to trophocyte invasiveness
Bioinformatic analysis discovery, miR-181b between different plant species (people, rat, mouse, zebra fish) protect by height
It keeps, and homology is in 95% or more (referring to table 1), it is meant that the importance of its potential function.But Literature Material is found, at present simultaneously
The not report about miR-181b and the research of trophocyte invasiveness.
1 miR-181b species conservative Analysis of table
In order to obtain more support foundations, we are thin as tool using two kinds high invasion JEG-3, HTR-8/Svneo cells
Born of the same parents take the strategy of overexpression and silencing to change the expression of miR-181b in cell.
1.miR-181b being overexpressed the influence to trophocyte invasiveness:
MiR-181b Lentiviral is constructed, unloaded slow virus is control, is coated with into lentiviral particle, infects respectively
JEG-3 and HTR-8/SVneo trophocyte, mtt assay exclude influence of the transfection toxicity to cell;Using Real time PCR skill
Art is verified intracellular mature miR-181b and is overexpressed.Main assessment: trophocyte invasiveness: Transwell method detects HTR-8/
SVneo cell invasion function changes.
2.miR-181b influence of the expression silencing to trophocyte invasiveness:
The slow virus carrier of miR-181b expression silencing is constructed, unloaded slow virus is control, and coating is divided at lentiviral particle
Not Gan Ran JEG-3 and HTR-8/SVneo trophocyte, mtt assay excludes influence of the transfection toxicity to cell;Using Real time
Round pcr assesses the silence efficiency of intracellular miR-181b.Main assessment: trophocyte invasiveness: Transwell method detection
HTR-8/SVneo cell invasion function changes.
As a result, it has been found that the invasive ability of two kinds of cells is decreased obviously (Fig. 2 a, 2b) after up-regulation cell miR-181b expression
And the activity of Invasive associated protein MMP-2/MMP-9 also declines (Fig. 2 c).In figure: Blank is blank control group, and Scramble is
Negative control group, miR-181b are miR-181b mimics group, and HTR is the trophocyte strain of HTR-8/Svneo villi.
The analysis of the downstream effects target spot of embodiment 4:miR-181b
The specific mechanism that MiR-181b influences trophocyte invasiveness is still not clear, for this purpose, we believe by biology first
The method of credit analysis is ceased, searching regulates and controls target downstream.Software analysis shows that: CXCL3, S1PR1, PPP3R1 gene are in 3 ' UTR
Containing the core sequence " GAAUGU " (see Fig. 3 a) in conjunction with miR-181b, and CXCL3, S1PR1, PPP3R1 base has been reported
Because both participating in the adjusting of trophocyte function.Therefore we choose these three genes and further investigate, by the miR- of foundation
181b is overexpressed JEG-3, HTR-8/Svneo cell, and detection three expresses variation.As a result, it has been found that CXCL3, PPP3R1 not by
MiR-181b influences (see Fig. 4 b, 4c), and S1PR1 is expressed in two kinds of cells and is remarkably decreased (see Fig. 4 a), prompts S1PR1 can
It can be the direct action target spot of miR-181b.In Fig. 4: Blank is blank control group, and Scramble is negative control group, miR-
181b is miR-181b mimics group, and JEG-3 is the trophocyte strain of suede cancer, and HTR is that HTR-8/Svneo villi nourishes carefully
Born of the same parents' strain.
More direct experimental verification is the target base of miR-181b by UTR luciferase report gene experimental verification S1PR1
Cause: pass through building miR-181b analogies (mimics), the luciferase report gene sequence (wild type) of the UTR Han S1PR13 '
And canonical sequence (saltant type), transfected HEK 293 and HTR-8/SVneo trophocyte;Hybridization in situ detects miR-181b
Expression, Immunohistochemical Method detect the expression of S1PR1;The variation of luciferase activity is detected to verify miR-181b to S1PR1 table
The regulating and controlling effect reached.The result shows that: the overexpression of miR-181b causes the expression of S1PR1 to reduce.
Further to prove S1PR1 and trophocyte invasiveness relationship, the tissue expression rule of S1PR1, Wo Menjian are explored
Its expression in placenta of preeclampsia, spontaneous abortion villus and suede cancerous tissue is surveyed.It was found that the group that S1PR1 is reduced in invasiveness
It knits in (placenta of preeclampsia and spontaneous abortion villus) and lowers (see Fig. 5), in the raised tissue (suede cancer) of invasiveness in expression
It adjusts (see Fig. 5), with miR-181b expression rule on the contrary, meeting its control methods.In Fig. 5: NP is normal placenta, and PE is before eclampsia
Phase placenta, CH are suede cancerous tissue, and SA is spontaneous abortion villus, and NV is regions in first-trimester villi.Knot is analysed and tested in conjunction with above- mentioned information credit
Fruit, we tentatively judge S1PR1 for the downstream effects target spot of miR-181b.
In order to further judge a possibility that S1PR1 influences trophocyte invasiveness as miR-181b downstream target gene,
We are proved from the angle of biological information and gene function again.TargetScan on-line analysis finds S1PR1 and miR-
The binding sequence " GAAUGU " of 181b highly conserved (see Fig. 3 b) in multiple species;Literature Material discovery, S1PR1 full name sheath
Ammonia alcohol kinases receptors (Sphingosine-1-phosphate receptor), can be by activating in conjunction with its ligand S1P
MEK-ERK-MMP-2 signal path influences HepG2 (liver cancer cell lines), MCF10A (galactophore epithelial cell system) and trophocyte
Migration and invasion.So far, it is believed that existing adequate cause thinks that S1PR1 is the target gene in the downstream miR-181b.
Based on above-mentioned analysis and experimental result, it is proposed that " miR-181b regulates and controls S1PR1 expression, influences trophocyte and invades
Power is attacked, the generation of pregnancy related disorder is participated in ".
Although the embodiments of the present invention have been disclosed as above, but its is not only in the description and the implementation listed
With.It can be applied to various suitable the field of the invention completely.It for those skilled in the art, can be easily
Realize other modification.Therefore without departing from the general concept defined in the claims and the equivalent scope, the present invention is simultaneously unlimited
In specific details and legend shown and described herein.
Claims (9)
1. a kind of application of miRNA marker in the diagnostic reagent for preparing trophocyte invasiveness exception related disease, special
Sign is that the marker is miR-181b.
2. the reagent of the expression for measuring miR-181b is in manufacture for predicting that it is different that trophocyte invasiveness occurs for object
Application in the kit of a possibility that normal related disease, wherein if the expression of miR-181b is aobvious relative to normal control
It writes and increases or reduce, it is considered that the object increases a possibility that trophocyte invasiveness exception related disease occurs.
3. application according to claim 1 or 2, the disease is selected from spontaneous abortion, preeclampsia, suede cancer.
4. a kind of diagnostic kit of trophocyte invasiveness exception related disease, it is characterised in that the kit contains detection
The reagent of miR-181b.
5. kit according to claim 4, the disease is selected from spontaneous abortion, preeclampsia, suede cancer.
Application of the 6.miR-181b in the reagent that preparation adjusts S1PR1 expression, wherein the examination for being overexpressed miR-181b
Agent causes the expression of S1PR1 to decline, and the expression for making the reagent of miR-181b low expression lead to S1PR1 rises.
7. application according to claim 6, the reagent be used to change trophocyte invasiveness.
8. application according to claim 6 or 7, the reagent be used to treat the extremely related disease of trophocyte invasiveness
Disease.
9. application according to claim 8, the disease is selected from spontaneous abortion, preeclampsia, suede cancer.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810643550.3A CN108949973B (en) | 2018-06-21 | 2018-06-21 | The biomarker of trophocyte invasiveness exception and its application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810643550.3A CN108949973B (en) | 2018-06-21 | 2018-06-21 | The biomarker of trophocyte invasiveness exception and its application |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108949973A true CN108949973A (en) | 2018-12-07 |
CN108949973B CN108949973B (en) | 2019-10-11 |
Family
ID=64491995
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810643550.3A Expired - Fee Related CN108949973B (en) | 2018-06-21 | 2018-06-21 | The biomarker of trophocyte invasiveness exception and its application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108949973B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112180098A (en) * | 2019-12-06 | 2021-01-05 | 中山大学 | Screening method of placenta-related disease marker and marker |
CN112961913A (en) * | 2021-02-05 | 2021-06-15 | 山东大学第二医院 | Application of lncRNA in diagnosis and treatment of recurrent abortion |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102230006A (en) * | 2011-06-10 | 2011-11-02 | 蒋敬庭 | Method and kit for determining curative effects of stomach cancers and application method of kit |
CN102301002A (en) * | 2008-11-12 | 2011-12-28 | 卡里斯生命科学卢森堡控股有限责任公司 | Methods and systems of using exosomes for determining phenotypes |
-
2018
- 2018-06-21 CN CN201810643550.3A patent/CN108949973B/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102301002A (en) * | 2008-11-12 | 2011-12-28 | 卡里斯生命科学卢森堡控股有限责任公司 | Methods and systems of using exosomes for determining phenotypes |
CN102230006A (en) * | 2011-06-10 | 2011-11-02 | 蒋敬庭 | Method and kit for determining curative effects of stomach cancers and application method of kit |
Non-Patent Citations (4)
Title |
---|
AMERIGO MICRO DI MACRO等: "impact of BCR stimulation on miR-181b in chronic lymphocityc leukemia", 《BLOOD》 * |
HARAPAN等: "the role of microRNAs in the proliferation,differentiation,invasion,and apoptosis of trophoblasts during the occurrence of preeclampsia—A systematic review", 《TZU CHI MEDICAL JOURNAL》 * |
YAN-SHAN CHEN等: "levels of microRNA-181b and plasminogen activator inhibitor-1 are associated with hypertensive disorders complicating pregnancy", 《EXPERIMENTAL AND THERAPEUTIC MEDICINE》 * |
安刚等: "miRNA在子痫前期发病与诊断中的意义", 《现代妇产科进展》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112180098A (en) * | 2019-12-06 | 2021-01-05 | 中山大学 | Screening method of placenta-related disease marker and marker |
CN112180098B (en) * | 2019-12-06 | 2023-02-17 | 中山大学 | Screening method of placenta-related disease marker and marker |
CN112961913A (en) * | 2021-02-05 | 2021-06-15 | 山东大学第二医院 | Application of lncRNA in diagnosis and treatment of recurrent abortion |
CN112961913B (en) * | 2021-02-05 | 2021-10-22 | 山东大学第二医院 | Application of lncRNA in diagnosis and treatment of recurrent abortion |
Also Published As
Publication number | Publication date |
---|---|
CN108949973B (en) | 2019-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103602724B (en) | Determine the method for hepatocellular carcinoma hypotype and detection liver-cancer stem cell | |
CN109890394A (en) | The Microrna of biomarker as endometriosis | |
ES2632212T3 (en) | miR-135 and compositions comprising it for the treatment of medical conditions associated with serotonin | |
CN108535465A (en) | The composition and method of prediction drug susceptibility, resistance and progression of disease | |
CN105980576A (en) | Method For The Prognosis And Treatment Of Cancer Metastasis | |
AU2012345666A1 (en) | Targeting microRNAs miR-409-5p, miR-379 and miR-154* to treat prostate cancer bone metastasis and drug resistant lung cancer | |
WO2021052286A1 (en) | New exosome-releasing-related targets and use thereof in monitoring and inhibiting tumors | |
CN102892898B (en) | For the diagnostic kit containing microRNA biomarker and the method for diagnosis of hepatoma | |
Li et al. | High expression of vinculin predicts poor prognosis and distant metastasis and associates with influencing tumor-associated NK cell infiltration and epithelial-mesenchymal transition in gastric cancer | |
CN110225984A (en) | Identify the method and therapeutic choice of risk of cancer | |
CN109468382B (en) | Application of lncRNA in diagnosis and treatment of lung adenocarcinoma | |
Xing et al. | Klf5 Deletion Promotes Pten Deletion–Initiated Luminal-Type Mouse Prostate Tumors through Multiple Oncogenic Signaling Pathways | |
CN108949973B (en) | The biomarker of trophocyte invasiveness exception and its application | |
CN109423517A (en) | Purposes of the excretion body in diagnosing tumor, treatment and prognosis evaluation | |
Mikkelsen | Molecular biology in conjunctival melanoma and the relationship to mucosal melanoma | |
Tosevska et al. | Cell-free RNA as a novel biomarker for response to therapy in head & neck cancer | |
CN102399870B (en) | Reagent for determining survival and prognosis of patients with esophagus cancer | |
CN107937526A (en) | A kind of relevant tumor markers of neuroblastoma and its application | |
Wang et al. | Down-regulation of CX43 expression by miR-1 inhibits the proliferation and invasion of glioma cells | |
CN104884097B (en) | For drug resistant breast cancer prognosis and treatment as the miRNA for newly treating auxiliary agent and biomarker | |
EP2942399B1 (en) | Method for the diagnosis of breast cancer | |
CN110042164B (en) | Lung cancer diagnosis and treatment lncRNA marker | |
Peng et al. | Identification and validation of miRNA-TF-mRNA regulatory networks in uterine fibroids | |
US10167516B2 (en) | Six-gene biomarker of survival and response to platinum based chemotherapy in serious ovarian cancer patients | |
CN117887845B (en) | Application of STK24 in liver cancer radiotherapy sensitivity assessment and radiotherapy sensitization |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20191011 |